Tag:
PATH Malaria Vaccine Initiative
Latest Headlines
Latest Headlines
GSK malaria vaccine works in major Phase III trial
In a late-stage trial of 6,000 children, three doses of GlaxoSmithKline's malaria vaccine RTS,S (also known as Mosquirix ) cut the risk of children contracting malaria in a follow-up conducted
J&J, GSK team on malaria vaccine
The PATH Malaria Vaccine Initiative (MVI) is collaborating with GlaxoSmithKline and Johnson & Johnson's vaccine unit Crucell to test second-generation version of GSK's experimental malaria
GAVI Alliance pours $100M into meningitis vaccine
The GAVI Alliance has committed $100 million to support a meningitis A vaccine called MenAfriVac developed by Seattle-based PATH. The vaccine, which was developed with the help of a $70 million
PATH to use Liquidia particle technology for malaria
The PATH Malaria Vaccine Initiative (MVI) will have use of Liquidia Technologies' PRINT particle technology for its research into new, more effective malaria vaccines. The technology helps
Merck joins PATH on next-gen malaria vax program
Merck ( $MRK ) has signed on to work with the groundbreaking PATH Malaria Vaccine Initiative and the NYU Langone Medical Center on a next-generation malaria vaccine that will attempt to ward off the
Breakthrough meningitis vaccine costs only 50 cents a jab
Working with money from the Bill and Melinda Gates Foundation , a team of experts from Seattle-based PATH and the World Health Organization were able to develop a new vaccine for meningitis that costs
Crucell gains key support for malaria vaccine program
The Dutch biotech Crucell has picked up financial support for its malaria vaccine program through a newly inked collaboration with the PATH Malaria Vaccine Initiative and USAID's Malaria Vaccine
GSK begins phase III global trial for malaria vax
GlaxoSmithKline is pushing forward with the final stages of pre-approval development of its malaria vaccine candidate Mosquirix. Scientists began injecting 1,200 infants and children involved in its
Sanaria starts adult trial of malaria vax
Rockville, MD-based Sanaria has launched a Phase I trial of its malaria vaccine candidate in adults. Working with the backing of the PATH Malaria Vaccine Initiative , Sanaria is recruiting 104
New collaboration aims at next-gen malaria vaccine
PATH Malaria Vaccine Initiative and the Seattle Biomedical Research Institute are poised to announce a new collaboration this morning aimed at developing a next-generation malaria vaccine.
